SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma

Until recently, advances in classical Hodgkin lymphoma (HL) treatment primarily consisted of minor modifications of highly effective decades-old chemotherapy and radiation approaches. In early stage disease, excellent outcomes have been reported with fewer cycles of chemotherapy, lower doses and smaller radiation fields, and in some circumstances radiation elimination. In advanced stage disease, maintaining dose intensity of standard chemotherapy regimens has resulted in modest improvements in outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research

Related Links:

Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): Steven M. Bair, Anthony Mato, Jakub SvobodaAbstractClassical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Although most patients are cured with standard first-line therapy, up to 20% of patients will have relapsed or refractory disease. Although the conventional approach to treatment has consisted of chemotherapy, radiation, and for those who relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and checkpo...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAutologous HCT is an effective therapy for refractory/relapsed HAL with manageable toxicity, similar to non-HIV patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: June 2018Source: Clinical Lymphoma Myeloma and Leukemia, Volume 18, Issue 6Author(s): Steven M. Bair, Anthony Mato, Jakub SvobodaAbstractClassical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Although most patients are cured with standard first-line therapy, up to 20% of patients will have relapsed or refractory disease. Although the conventional approach to treatment has consisted of chemotherapy, radiation, and for those who relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and checkpo...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAutologous HCT is an effective therapy for refractory/relapsed HAL with manageable toxicity, similar to non-HIV patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
There is a known association between Hodgkin lymphoma (HL) and autoimmune disorders with several case reports and case series describing diseases such as immune thrombocytopenia (ITP) in patients with HL, as well as population studies depicting a link between these phenomena. The following case report describes a patient initially presenting with ITP and subsequently being diagnosed with HL as well as primary biliary cirrhosis (PBC) and Hashimoto ’s thyroiditis. This case is unique as it is one of only a few case reports describing multiple autoimmune conditions in one patient with HL and in this scenario, the thromb...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
1428Purpose: The graded visual assessment Deauville five-point scale(5-PS) has been widely accepted to assessment in patients with Hodgkin lymphoma. The visual assessment only with PET which the unique technique can do the quantitative analysis can not show all its abilities. We want to evaluate the predictive role of the graded visual assessment Deauville five-point scale added quantitative analysis for Hodgkin lymphoma treatment. Methods: Consecutive 42 patients by Hodgkin lymphoma from our center diagnosed between December 2011 and January 2017 were retrospectively enrolled. No change to treatment based on interim-PET r...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma Poster Session Source Type: research
Conclusions We successfully used textural features calculated from baseline 18F-FDG PET/CT scans to classify patients according to Deauville criteria and to classify lesions according to histopathology with high accuracy. Studies with larger samples are needed to verify these findings.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Leukemia/Lymphoma/Myeloma I Source Type: research
Publication date: Available online 31 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Steven M. Bair, Anthony Mato, Jakub Svoboda Classical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Though the majority of patients are cured with standard frontline therapy, up to 20% of patients will have relapsed or refractory disease. Though the conventional approach to treatment has consisted of chemotherapy, radiation, and for those that relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and chec...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our results are encouraging and justify evaluation of TECAM versus BEAM (carmustine, etoposide, cytarabine, melphalan) in a prospective multicenter study in a large homogenous patient population. Micro-Abstract High-dose chemotherapy and autologous stem cell transplantation (ASCT) is the current standard of care for relapsed lymphoma. We retrospectively analyzed the data from 212 lymphoma patients who had undergone ASCT with the TECAM conditioning regimen. The 3-year overall survival, progression-free survival, and death resulting from treatment were comparable to those reported with other conditioning regimens....
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Low-dose RT, administered to all sites of original involvement, was associated with improved PFS, even in the setting of a metabolic CR after ABVD. Micro-Abstract The role of consolidation radiation therapy (RT) in advanced Hodgkin lymphoma is controversial, especially if a complete response (CR) is achieved according to positron emission tomography-computed tomography imaging after chemotherapy. In this series, low-dose (approximately 20 Gy) RT to all sites of original disease improved progression-free survival, even in the setting of a CR after ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). Long-...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chemotherapy | Hematology | Hodgkin's Disease | Leukemia | Lymphoma | Myeloma